It’s certainly a little more ‘cruisy’ this morning.
I woke up yesterday thinking there was something seriously wrong with the brand new Iphone I had just purchased….
Turns out a major outage impacted millions of Optus customers nationally including businesses, Melbourne’s rail network and hospitals.
Services started to return to normal on Wednesday afternoon, almost nine hours after issues began. The full restoration of the network took about 16 hours.
In other news
Yesterday’s Small Caps highlights:
It was a good day for Golden State Mining (ASX:GSM), up after announcing a series of pegmatite dyke “swarms” at Paynes Find Central and Paynes Find North in the Murchison region of WA with samples off to the lab for lithium analysis and drilling likely early next year.
Technology is improving monitoring of pregnancy with medtech company focusing on maternity care, HeraMED (ASX:HMD), today announcing a trial for up to 90 pregnancies for six to nine months at Gold Coast Hospital to evaluate clinical useability, patient satisfaction, and economic analysis of the HeraCARE and HeraBEAT platforms.
Across markets
Australian share are poised to open higher, even as Wall Street fluctuated and as oil tumbled amid concerns about the outlook for global demand and interest rates.
Global benchmark Brent dropped more than 2 per cent slipping below $US80 a barrel for the first time since July. US benchmark West Texas Intermediate was below $US76 a barrel, down 2.8 per cent near 2.30pm in New York following a 4.3 per cent decline the previous session.
Gold dipped below $US1950 an ounce, after having flirted with a move above $US2000 late last month.
Shares in New York were struggling to extend their fast start to November. The NYSE Fang + Index was modestly higher as buying momentum eased. The yield on the US 10-year note continued to reset lower; it’s fallen 50 basis points from its October high.
Market highlights
ASX futures up 28 points or 0.4% to 7030 near 8am AEDT
- AUD -0.5% to 64.02 US cents
- Bitcoin +0.2% to $US35,627 at 8.14am AEDT
- On Wall St at 4pm: Dow -0.1% S&P +0.1% Nasdaq +0.1%
- In New York: BHP -0.8% Rio -0.3% Atlassian -2.5%
- Tesla -0.02% Apple +0.6% Amazon -0.4%
- VIX -2.6% QQQ +0.1% TLT +1.7%
- Stoxx 50 +0.6% FTSE -0.1% DAX +0.5% CAC +0.7%
- Spot gold -1% to $US1949.53/oz at 2.30pm in New York
- Brent crude -2.7% to $US79.43 a barrel
- Iron ore +1.1% to $US124.40 a tonne
- 10-year yield: US 4.51% Australia 4.58% Germany 2.61%
- US prices as of 4.10pm in New York
Source: AFR
- Paradigm Biopharmaceuticals is working to transform treatment for osteoarthritis
- In 2022, the global market for osteoarthritis therapeutics was valued at $8.28 billion
- Phase 2 trials of iPPS into osteoarthritis show pain reduction and functional improvement out to 12-months following a 6-week course of treatment.
- Phase 2 trials have also demonstrated iPPS improves the overall structure of the OA knee joint.
- Paradigm is currently conducting a global Phase 3 OA clinical trial.
Special Report: Frequently referred to degenerative joint disease or ‘wear and tear’, arthritis osteoarthritis is the most common form of arthritis. One ASX company is looking to diminish its impact by maintaining sufferers’ functional mobility and reducing pain.
Paradigm Biopharmaceuticals (ASX:PAR) is primarily focused on development of injectable pentosan polysulfate sodium (iPPS/Zilosul) for treatment of diseases such as osteoarthritis (OA) and Mucopolysaccharidosis (MPS) where inflammation plays a major pathogenic role.
Founded in 2014 and listing on the ASX in 2015, PAR recently unveiled positive new analysis from its phase 2 clinical trial of iPPS for treatment of OA in the knee, treating both symptoms along with preserving and/or regenerating joint tissues.
A single 6-week treatment course of (iPPS), which is demonstrating both anti-inflammatory and tissue regenerative properties, showed pain reduction and functional improvement effects through the 12-month study. Notably there was an increase of cartilage thickness from baseline as shown by MRI imaging at six months.
Source: Stockhead
Company: Alderan Resources (ASX:AL8)
Sector: Lithium
Deal Type: Placement
Raise Amount: $1.75M
Latest Entry Price: $0.006 with a 1:2 AL8OA
Today’s Price Change: $0.014 -6.67%
Company: Terra Uranium (ASX:T92)
Sector: Uranium
Deal Type: IPO
Raise Amount: $7.5M
Latest Entry Price: $0.20
Today’s Price Change: $0.13 Unchanged
Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.20
Today’s Price Change: $0.13 Unchanged
Company: Gold Mountain Limited (ASX:GMN)
Sector: Lithium
Deal Type: Placement
Raise Amount: $2.25M
Latest Entry Price: $0.0075
Today’s Price Change: $0.005 Unchanged
Company: Unith Ltd. (ASX:UNT)
Sector: AI/ChatGPT
Deal Type: Placement
Raise Amount: $4.5M
Latest Entry Price: $0.033 with a 1:1 UNTO
Today’s Price Change: $0.02 Unchanged
Company: Volt Resources Ltd. (ASX:VRC)
Sector: Battery Metals
Deal Type: Placement
Raise Amount: $5.75M
Latest Entry Price: $0.011
Today’s Price Change: $0.006 -14.29%
Company: Castle Minerals Ltd. (ASX:CDT)
Sector: Battery Metals/Base Metals
Deal Type: Placement
Raise Amount: $1.52M
Latest Entry Price: $0.02 with a 2:3 CDTOA
Today’s Price Change: $0.01 -16.67%
Company: Avenira Ltd. (ASX:AEV)
Sector: Phosphate
Deal Type: Placement
Raise Amount: $2.1M
Latest Entry Price: $0.01 with a 1:2 AEVO
Today’s Price Change: $0.013 +8.33%
Company: Latrobe Magnesium Ltd. (ASX:LMG)
Sector: Magnesium
Deal Type: Placement
Raise Amount: $3M & $11.5M
Latest Entry Price: $0.10 with a 1:4 LMGO
Today’s Price Change: $0.046 Unchanged
Company: Askari Metals Ltd (ASX:AS2)
Sector: Mining
Deal Type: IPO
Raise Amount: $5.7M
Latest Entry Price: $0.35 with a 1:3 AS2O
Today’s Price Change: $0.155 -6.06%
Company: iCandy (ASX:ICI)
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today’s Price Change: $0.033 +13.79%
Company: Fatfish Group (ASX:FFG)
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5M
Latest Entry Price: $0.015 with a 1:2 FFGOA
Today’s Price Change: $0.011 -8.33%
Company: Paradigm Biopharma (ASX:PAR)
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1M+
Latest Entry Price: $0.35
Today’s Price Change: $0.39 +0.63%
Company: ReNu Energy Limited (ASX:RNE)
Sector: Energy
Deal Type: Placement
Raise Amount: $1.46M
Latest Entry Price: $0.06 with a 1:1 RNEO
Today’s Price Change: $0.022 +10.00%
Company: Carly Holdings Ltd (ASX:CL8)
Sector: AI and Car subscription
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.025 with a 1:2 CL8O
Today’s Price Change: $0.017 Unchanged
Company: Avecho Biotechnology (ASX:AVE)
Sector: CBD
Deal Type: Placement
Raise Amount: $5M
Latest Entry Price: $0.006 with a 3:2 AVEOA
Today’s Price Change: $0.004 Unchanged
Company: ECS Botanics Holdings Ltd (ASX:ECS)
Sector: Medicinal Cannabis
Deal Type: Placement
Raise Amount: $6.6M
Latest Entry Price: $0.033 with 1:2 ECSO
Today’s Price Change: $0.022 -4.35%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak on 1300 304 460
No responses yet